ACCENTIA TO LICENSE ALL MAYO ANTIFUNGALS FOR CHRONIC SINUSITIS.

Biotech Business, September, 2006

Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), Tampa, Fla., has signed an amendment to its exclusive option agreement with the Mayo Foundation for Medical Research and Education (Mayo Clinic) to license any and all intranasal antifungals for chronic sinusitis. The amendment extends the exclusive option agreement an additional year and will expire December 6, 2007 beyond the anticipated date of an NDA filing for SinuNase(TM). Accentia is developing SinuNase under an exclusive worldwide license with the Mayo Clinic for the use of intranasal amphotericin B for refractory chronic sinusitis.

From the date of the amendment's signing until the expiration of the contract in 2007, Accentia has the exclusive option to license any and all antifungals, including...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.